Nationwide Recall of More Than 6,000 Blood Pressure Medication Bottles After Quality Testing Issue

A nationwide recall has been issued for more than 6,000 bottles of a prescription medication used to treat high blood pressure after quality testing revealed that one of its active ingredients failed to meet required standards. The recall affects a specific lot of Amlodipine and Olmesartan Medoxomil Tablets and has been classified by the U.S. Food and Drug Administration (FDA) as a Class II recall.

Patients currently taking the medication are encouraged to review the lot number on their prescription bottles and consult their pharmacist or healthcare provider if they have concerns. Health officials emphasize that people should not stop taking prescribed blood pressure medication without first seeking medical advice.

Why the Blood Pressure Medication Was Recalled

Ascend Laboratories LLC voluntarily recalled 6,192 bottles of Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg, after routine stability testing identified a problem with the olmesartan medoxomil ingredient.

According to the FDA recall notice, the affected ingredient failed dissolution testing. Dissolution testing measures how effectively a medication dissolves after it is taken. Medicines that do not dissolve properly may release their active ingredients more slowly than intended, which could reduce or delay their therapeutic effect.

While the recall does not indicate that the medication is contaminated or dangerous in the traditional sense, reduced effectiveness could be a concern for patients relying on the drug to manage hypertension.

What Is a Class II FDA Recall?

The FDA categorized the recall as a Class II recall on July 20. This classification means that exposure to the affected product may cause temporary or medically reversible health effects. The agency also notes that the likelihood of serious adverse health consequences is considered low.

Class II recalls typically involve products that present limited health risks but still require prompt corrective action to protect consumers.

What Medication Is Affected?

The recalled product is:

• Medication: Amlodipine and Olmesartan Medoxomil Tablets
• Strength: 10 mg/20 mg
• Bottle Size: 30 tablets
• National Drug Code (NDC): 67877-500-30
• Lot Number: 25121311
• Expiration Date: March 31, 2028

The medication has been distributed throughout the United States since August 11, 2025.

How the Medication Works

Amlodipine and Olmesartan Medoxomil Tablets combine two medications that help control high blood pressure through different mechanisms.

Amlodipine belongs to a class of medications called calcium channel blockers. It helps relax blood vessels, making it easier for blood to flow.

Olmesartan medoxomil is an angiotensin II receptor blocker, commonly known as an ARB. It blocks the action of a hormone that causes blood vessels to narrow, helping reduce blood pressure.

Together, these medications are commonly prescribed for patients whose blood pressure requires combination therapy.

What Patients Should Do

Patients taking this medication should first determine whether their prescription bottle matches the recalled lot number.

Healthcare experts generally recommend the following steps:

• Check the lot number and expiration date on the prescription bottle.
• Contact the dispensing pharmacy if the medication matches the recalled batch.
• Speak with a healthcare provider before making any changes to treatment.
• Continue taking the medication unless instructed otherwise by a medical professional.

The FDA warns that suddenly stopping blood pressure medication may increase health risks, including uncontrolled hypertension, which can raise the chances of heart attack, stroke, and other cardiovascular complications.

Who Manufactured the Recalled Medication?

The recalled tablets were manufactured by Alkem Laboratories Ltd. in India and distributed in the United States by Ascend Laboratories LLC, which is headquartered in Bedminster, New Jersey.

The recall was initiated on July 8 and remains ongoing.

Previous Recalls Involving the Same Medication

This is not the first recall involving Ascend Laboratories' combination blood pressure medication.

In May 2026, the company recalled 15,696 bottles of the 5 mg/40 mg strength after the olmesartan component also failed dissolution testing. That recall received the same Class II classification from the FDA.

Earlier, in July 2025, another 8,568 bottles of the 5 mg/40 mg version were recalled for similar dissolution testing failures.

The repeated recalls suggest an ongoing quality control issue affecting certain production batches rather than a problem with the medication itself as a whole.

Understanding Dissolution Testing

Dissolution testing is a standard quality control procedure used during pharmaceutical manufacturing. It measures how quickly a tablet dissolves under conditions that simulate the human digestive system.

Passing dissolution testing helps ensure that patients receive the intended amount of medication within the expected timeframe.

If a tablet dissolves too slowly, the active ingredient may not be absorbed as efficiently, potentially reducing the medicine's effectiveness. This is especially important for medications used to manage chronic conditions such as hypertension, where consistent drug performance is essential.

Why Blood Pressure Control Matters

Hypertension affects millions of adults and is a major risk factor for cardiovascular disease. Many patients require daily medication to keep their blood pressure within a healthy range.

Proper blood pressure control can help lower the risk of:

• Heart attack
• Stroke
• Heart failure
• Kidney disease
• Vision problems

Because of these risks, medical professionals generally advise patients not to discontinue prescribed blood pressure medication without guidance, even during a product recall.

Ongoing FDA Monitoring

The FDA continues to monitor pharmaceutical manufacturing quality through inspections, testing, and recall oversight. Drug recalls are issued when manufacturers or regulators identify problems that could affect product quality, safety, or effectiveness.

Patients who believe they have received the affected medication should work directly with their pharmacist and healthcare provider to determine the most appropriate course of action.

For individuals whose medication is not part of the recalled lot, no action is necessary.

Final Thoughts

The recall of more than 6,000 bottles of Amlodipine and Olmesartan Medoxomil Tablets highlights the importance of ongoing quality testing in pharmaceutical manufacturing. Although the FDA considers the risk of serious harm to be low, affected patients should verify whether their medication is included in the recall and seek professional medical advice if necessary.

Maintaining consistent blood pressure treatment remains essential, and patients should avoid stopping their medication unless directed by a qualified healthcare provider.

Source: U.S. Food and Drug Administration (FDA) recall notice and information reported by NTD Television.

Disclaimer: This article is intended for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult your physician, pharmacist, or another qualified healthcare professional before making any changes to your medications or treatment plan.